

Research Abstract Template

Submissions must not exceed 300 words (excluding title & authors). The document **must not** be password protected or saved as read only as this may result in your abstract failing to upload successfully. Use Calibri 11 point type only. Please structure your submission using the subheadings below. If the abstract does not fit the headings, please put full abstract beneath introduction and we will remove the headings once submitted.

MENTAL DISORDERS AND HEPATITIS C PREVALENCE IN PEOPLE ON OPIOID AGONISTE THERAPY FOLLOWED AT THE SAMMSU COHORT, SWITZERLAND.

Authors:

Castro E¹, Gueorguiev B², Bregenzer A³, Bruggmann P⁴, Della Santa P⁵, Hensel-Koch K⁶, Moriggia A⁷, Thurnheer MC⁸, Scheidegger C⁹, Combescuré C¹⁰ and Girardin F¹¹.

1 Private Practice, and Clinique virtuelle hépatite C, Lausanne

2 Université de Genève, Geneva

3 Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, Aarau

4 Arud Centre for Addiction Medicine, Zurich

5 Fondation Phénix, Geneva

6 Stiftung Suchthilfe, St. Gallen

7 Ingrado Servizi per le Dipendenze and Epatocentro Ticino SA, Lugano

8 Department of Infectious Diseases, University Hospital, Bern

9 Private Practice, Basel

10 Hôpitaux Universitaires de Genève, Geneva

11 Centre hospitalier universitaire vaudois

Background:

We have shown the cost-effectiveness of hepatitis C Virus (HCV) infection screening in psychiatric inpatients independently of current drug use. However, we lack knowledge on mental disorders possibly triggering risk behavior for hepatitis C infection. This study evaluates whether specific mental disorders are associated with hepatitis C prevalence in the SAMMSU cohort in order to provide Swiss guidance.

Methods:

We analyzed data from 825 patients on opioid substitution treatment followed between 2014 to 2019 in the SAMMSU cohort. Follow-up consisted of annual visits for drug use, mental disorders (ICD-10 /F10-19) and HCV antibody screening among other health conditions. Disease-10 Risk ratios and stratification analyses were calculated using HCV prevalence and mental disorders (MD). Patients were followed longitudinally to evaluate the risks of drug use, HCV-sero-prevalence, MD categories and risk ratios (RR) were calculated using patients with drug use only as reference group.

Results:

At least one additional MD was recorded in 72% of the 825 SAMMSU participants. Mood disorder was found in 45% with a RR = 0.90 [95%-CI: 0.75 - 1.09], personality and behavior disorder in 30% with a RR = 1.31 [95%-CI: 0.95 - 1.83] and 17% schizophrenia or delusional disorders, with a RR=0.69 [95%-CI: 0.53 - 0.92] for positive HCV antibodies, respectively. HCV prevalence was 75.97% in the reference group and 70.82% among patients with ≥ 2 MD.

In addition to history of opioid use disorder, 34% of patients reported use of benzodiazepines (RR=1.40 [95%-CI: 1.04 - 1.87]), 54% of cannabis and derivatives (RR=1.28 [95%-CI: 1.04 - 1.57]) and 46% of cocaine (RR=1.29 [95%-CI: 1.02 - 1.62]).

Conclusion:

Schizophrenia and delusional disorders were negatively associated with HCV, whereas personality and behavior disorders were positively associated with HCV prevalence. Overall, HCV antibody prevalence was higher in patients with multiple drug use patterns.

Research Abstract Template

Submissions must not exceed 300 words (excluding title & authors). The document **must not** be password protected or saved as read only as this may result in your abstract failing to upload successfully. Use Calibri 11 point type only. Please structure your submission using the subheadings below. If the abstract does not fit the headings, please put full abstract beneath introduction and we will remove the headings once submitted.

Disclosure of Interest Statement: *See example below:*

The conference collaborators recognise the considerable contribution that industry partners make to professional and research activities. We also recognise the need for transparency of disclosure of potential conflicts of interest by acknowledging these relationships in publications and presentations.

Note: If accepted into the program you will be requested to include a disclosure of interest slide into your presentation or include such statements in your poster.